Walleye Capital
KYMR icon

Walleye Capital’s Kymera Therapeutics KYMR Stock Holding History

Walleye Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,000
Closed -$29.6K – 4611
2023
Q1 		$29.6K Buy
+1,000
New +$32.3K ﹤0.01% 3318

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Walleye Capital's KYMR Position: Q1 2026 in Review

Walleye Capital sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 19,181 shares — an estimated $1.49M sold.

Walleye Capital first reported a position in KYMR in Q1 2021 and held it in 6 quarters. The position peaked at $1.49M in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Walleye Capital reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 19,181 Kymera Therapeutics shares in Q1 2026, an estimated $1.49M.
  • Walleye Capital first reported a position in Kymera Therapeutics in Q1 2021 and held it in 6 quarters.
  • Walleye Capital's Kymera Therapeutics position peaked at $1.49M in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.